<?xml version="1.0" ?><!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st June 2018//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_180601.dtd"><PubmedArticleSet><PubmedArticle>    <MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM">        <PMID Version="1">30083053</PMID>        <DateRevised>            <Year>2018</Year>            <Month>08</Month>            <Day>09</Day>        </DateRevised>        <Article PubModel="Electronic-eCollection">            <Journal>                <ISSN IssnType="Print">1177-2719</ISSN>                <JournalIssue CitedMedium="Print">                    <Volume>13</Volume>                    <PubDate>                        <Year>2018</Year>                    </PubDate>                </JournalIssue>                <Title>Biomarker insights</Title>                <ISOAbbreviation>Biomark Insights</ISOAbbreviation>            </Journal>            <ArticleTitle>Development of a Novel Proteomic Risk-Classifier for Prognostication of Patients With Early-Stage Hormone Receptor-Positive Breast Cancer.</ArticleTitle>            <Pagination>                <MedlinePgn>1177271918789100</MedlinePgn>            </Pagination>            <ELocationID EIdType="doi" ValidYN="Y">10.1177/1177271918789100</ELocationID>            <Abstract>                <AbstractText>Use of proteomic strategies to identify a risk classifier that estimates probability of distant recurrence in early-stage hormone receptor (HR)-positive breast cancer is relevant to physiological cellular function and therefore to intrinsic tumor biology. We used a 298-sample retrospective training set to develop an immunohistochemistry-based novel risk classifier called CanAssist-Breast (CAB) which combines 5 prognostically relevant biomarkers and 3 clinico-pathological parameters to arrive at probability of distant recurrence within 5 years from diagnosis. Five selected biomarkers, namely, CD44, ABCC4, ABCC11, N-cadherin, and pan-cadherin, were chosen based on their role in tumor metastasis. The chosen biomarkers represent the hallmarks of cancer and are distinct from other proliferation and gene expression-based prognostic signatures. The 3 clinico-pathological parameters integrated into the machine learning-based CAB algorithm are tumor size, tumor grade, and node status. These features are used to calculate a &quot;CAB risk score&quot; that classifies patients into low- or high-risk groups and predicts probability of distant recurrence in 5 years. Independent clinical validation of CAB in a retrospective study comprising 196 patients indicated that distant metastasis-free survival (DMFS) was significantly different in the 2 risk groups. The difference in DMFS between the low- and high-risk categories was 19% in the validation cohort (<i>P</i> = .0002). In multivariate analysis, CAB risk score was the most significant independent predictor of distant recurrence with a hazard ratio of 4.3 (<i>P</i> = .0003). CanAssist-Breast is a precise and unique machine learning-based proteomic risk-classifier that can assist in risk stratification of patients with early-stage HR+ breast cancer.</AbstractText>            </Abstract>            <AuthorList CompleteYN="Y">                <Author ValidYN="Y">                    <LastName>Ramkumar</LastName>                    <ForeName>Charusheila</ForeName>                    <Initials>C</Initials>                    <AffiliationInfo>                        <Affiliation>OncoStem Diagnostics, Bangalore, India.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Buturovic</LastName>                    <ForeName>Ljubomir</ForeName>                    <Initials>L</Initials>                    <AffiliationInfo>                        <Affiliation>Clinical Persona, Inc., East Palo Alto, CA, USA.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Malpani</LastName>                    <ForeName>Sukriti</ForeName>                    <Initials>S</Initials>                    <AffiliationInfo>                        <Affiliation>OncoStem Diagnostics, Bangalore, India.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Kumar Attuluri</LastName>                    <ForeName>Arun</ForeName>                    <Initials>A</Initials>                    <AffiliationInfo>                        <Affiliation>OncoStem Diagnostics, Bangalore, India.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Basavaraj</LastName>                    <ForeName>Chetana</ForeName>                    <Initials>C</Initials>                    <AffiliationInfo>                        <Affiliation>OncoStem Diagnostics, Bangalore, India.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Prakash</LastName>                    <ForeName>Chandra</ForeName>                    <Initials>C</Initials>                    <AffiliationInfo>                        <Affiliation>OncoStem Diagnostics, Bangalore, India.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Madhav</LastName>                    <ForeName>Lekshmi</ForeName>                    <Initials>L</Initials>                    <AffiliationInfo>                        <Affiliation>OncoStem Diagnostics, Bangalore, India.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Doval</LastName>                    <ForeName>Dinesh Chandra</ForeName>                    <Initials>DC</Initials>                    <AffiliationInfo>                        <Affiliation>Chair Medical Oncology &amp; Chief of Breast &amp; Thoracic Services, Rajiv Gandhi Cancer Institute and Research Centre, New Delhi, India.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Mehta</LastName>                    <ForeName>Anurag</ForeName>                    <Initials>A</Initials>                    <AffiliationInfo>                        <Affiliation>Director Department of Laboratory &amp; Transfusion Services and Director Research, Rajiv Gandhi Cancer Institute and Research Centre, New Delhi, India.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Bakre</LastName>                    <ForeName>Manjiri M</ForeName>                    <Initials>MM</Initials>                    <AffiliationInfo>                        <Affiliation>OncoStem Diagnostics, Bangalore, India.</Affiliation>                    </AffiliationInfo>                </Author>            </AuthorList>            <Language>eng</Language>            <PublicationTypeList>                <PublicationType UI="D016428">Journal Article</PublicationType>            </PublicationTypeList>            <ArticleDate DateType="Electronic">                <Year>2018</Year>                <Month>07</Month>                <Day>30</Day>            </ArticleDate>        </Article>        <MedlineJournalInfo>            <Country>United States</Country>            <MedlineTA>Biomark Insights</MedlineTA>            <NlmUniqueID>101288638</NlmUniqueID>            <ISSNLinking>1177-2719</ISSNLinking>        </MedlineJournalInfo>        <CommentsCorrectionsList>            <CommentsCorrections RefType="Cites">                <RefSource>Asian Pac J Cancer Prev. 2011;12(3):625-9</RefSource>                <PMID Version="1">21627355</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Biomark Cancer. 2013 Oct 29;5:61-70</RefSource>                <PMID Version="1">24250234</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Clin Oncol. 2009 Mar 10;27(8):1160-7</RefSource>                <PMID Version="1">19204204</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>JAMA Oncol. 2018 Apr 1;4(4):545-553</RefSource>                <PMID Version="1">29450494</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Exp Oncol. 2011 Mar;33(1):42-6</RefSource>                <PMID Version="1">21423094</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Natl Cancer Inst. 2006 Sep 6;98(17):1183-92</RefSource>                <PMID Version="1">16954471</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Lancet. 2011 Aug 27;378(9793):771-84</RefSource>                <PMID Version="1">21802721</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Nature. 2000 Aug 17;406(6797):747-52</RefSource>                <PMID Version="1">10963602</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Ann N Y Acad Sci. 2004 Apr;1014:155-63</RefSource>                <PMID Version="1">15153430</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Cell. 2000 Jan 7;100(1):57-70</RefSource>                <PMID Version="1">10647931</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>N Engl J Med. 2007 Jan 18;356(3):217-26</RefSource>                <PMID Version="1">17229949</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Natl Cancer Inst. 2009 Nov 4;101(21):1446-52</RefSource>                <PMID Version="1">19815849</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Cell. 2011 Mar 4;144(5):646-74</RefSource>                <PMID Version="1">21376230</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Clin Oncol. 2011 Nov 10;29(32):4279-85</RefSource>                <PMID Version="1">21990395</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Cancer Lett. 2016 Jan 1;370(1):153-64</RefSource>                <PMID Version="1">26499806</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>BMC Cancer. 2014 Mar 19;14:211</RefSource>                <PMID Version="1">24645668</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Cell Sci. 2016 May 1;129(9):1751-8</RefSource>                <PMID Version="1">27084578</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Curr Opin Cell Biol. 2005 Oct;17(5):499-508</RefSource>                <PMID Version="1">16107313</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Am J Pathol. 1996 Nov;149(5):1519-30</RefSource>                <PMID Version="1">8909242</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Clin Oncol. 2006 Aug 10;24(23):3726-34</RefSource>                <PMID Version="1">16720680</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>N Engl J Med. 2004 Dec 30;351(27):2817-26</RefSource>                <PMID Version="1">15591335</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>PLoS Comput Biol. 2011 Oct;7(10):e1002240</RefSource>                <PMID Version="1">22028643</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Br J Cancer. 2013 Dec 10;109(12):2959-64</RefSource>                <PMID Version="1">24157828</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Expert Opin Ther Targets. 2015;19(12):1587-91</RefSource>                <PMID Version="1">26374284</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Drug Resist Updat. 2016 May;26:1-9</RefSource>                <PMID Version="1">27180306</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>N Engl J Med. 2015 Nov 19;373(21):2079-80</RefSource>                <PMID Version="1">26412350</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Lancet. 2005 May 14-20;365(9472):1687-717</RefSource>                <PMID Version="1">15894097</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>BMC Bioinformatics. 2008 Jul 22;9:319</RefSource>                <PMID Version="1">18647401</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Comb Chem High Throughput Screen. 2005 Dec;8(8):807-10</RefSource>                <PMID Version="1">16464168</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Stem Cells Int. 2016;2016:2087204</RefSource>                <PMID Version="1">27200096</PMID>            </CommentsCorrections>        </CommentsCorrectionsList>        <KeywordList Owner="NOTNLM">            <Keyword MajorTopicYN="N">early breast cancer</Keyword>            <Keyword MajorTopicYN="N">immunohistochemistry</Keyword>            <Keyword MajorTopicYN="N">machine learning</Keyword>            <Keyword MajorTopicYN="N">prognosis</Keyword>            <Keyword MajorTopicYN="N">recurrence risk classification</Keyword>        </KeywordList>        <CoiStatement>Declaration of conflicting interests:The author(s) declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: All authors except D.C.D. and A.M. are current or former employees/consultants at OncoStem Diagnostics Private Limited which has developed the CanAssist-Breast risk classifier. M.M.B. and C.R. are co-inventors on a patent application related to this article. All other authors have no other competing interests to declare.</CoiStatement>    </MedlineCitation>    <PubmedData>        <History>            <PubMedPubDate PubStatus="received">                <Year>2018</Year>                <Month>03</Month>                <Day>28</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="accepted">                <Year>2018</Year>                <Month>06</Month>                <Day>26</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="entrez">                <Year>2018</Year>                <Month>8</Month>                <Day>8</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="pubmed">                <Year>2018</Year>                <Month>8</Month>                <Day>8</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="medline">                <Year>2018</Year>                <Month>8</Month>                <Day>8</Day>                <Hour>6</Hour>                <Minute>1</Minute>            </PubMedPubDate>        </History>        <PublicationStatus>epublish</PublicationStatus>        <ArticleIdList>            <ArticleId IdType="pubmed">30083053</ArticleId>            <ArticleId IdType="doi">10.1177/1177271918789100</ArticleId>            <ArticleId IdType="pii">10.1177_1177271918789100</ArticleId>            <ArticleId IdType="pmc">PMC6066801</ArticleId>        </ArticleIdList>    </PubmedData></PubmedArticle></PubmedArticleSet>